These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 31494713)

  • 1. Spinal cord lesions are frequently asymptomatic in relapsing-remitting multiple sclerosis: a retrospective MRI survey.
    Granella F; Tsantes E; Graziuso S; Bazzurri V; Crisi G; Curti E
    J Neurol; 2019 Dec; 266(12):3031-3037. PubMed ID: 31494713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spinal cord MRI activity in multiple sclerosis: Predictive value for relapses and impact on treatment decisions.
    Lorefice L; Piras C; Sechi V; Barracciu MA; Cocco E; Fenu G
    J Neurol Sci; 2024 Jul; 462():123057. PubMed ID: 38820738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple sclerosis lesions and atrophy in the spinal cord: Distribution across vertebral levels and correlation with disability.
    Bussas M; El Husseini M; Harabacz L; Pineker V; Grahl S; Pongratz V; Berthele A; Riederer I; Zimmer C; Hemmer B; Kirschke JS; Mühlau M
    Neuroimage Clin; 2022; 34():103006. PubMed ID: 35468568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis.
    Dekker I; Sombekke MH; Witte BI; Geurts JJ; Barkhof F; Uitdehaag BM; Killestein J; Wattjes MP
    Mult Scler; 2018 Apr; 24(4):481-490. PubMed ID: 29106327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.
    Rocca MA; Valsasina P; Meani A; Gobbi C; Zecca C; Rovira À; Montalban X; Kearney H; Ciccarelli O; Matthews L; Palace J; Gallo A; Bisecco A; Gass A; Eisele P; Lukas C; Bellenberg B; Barkhof F; Vrenken H; Preziosa P; Comi G; Filippi M;
    Neurology; 2019 Nov; 93(20):e1852-e1866. PubMed ID: 31611336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of spinal cord lesion measures in early relapsing-remitting multiple sclerosis.
    Lauerer M; McGinnis J; Bussas M; El Husseini M; Pongratz V; Engl C; Wuschek A; Berthele A; Riederer I; Kirschke JS; Zimmer C; Hemmer B; Mühlau M
    J Neurol Neurosurg Psychiatry; 2023 Dec; 95(1):37-43. PubMed ID: 37495267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spinal cord size as promising biomarker of disability outcomes after hematopoietic stem cell transplantation in multiple sclerosis.
    Mariottini A; Stack EH; Nair G; Nozzoli C; Wu T; Marchi L; Boncompagni R; Repice AM; Fainardi E; Pasquale FD; Carlesi E; Saccardi R; Jacobson S; Massacesi L
    Mult Scler Relat Disord; 2024 Aug; 88():105745. PubMed ID: 38996712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis.
    Zecca C; Disanto G; Sormani MP; Riccitelli GC; Cianfoni A; Del Grande F; Pravatà E; Gobbi C
    Mult Scler; 2016 May; 22(6):782-91. PubMed ID: 26459149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Joint assessment of brain and spinal cord motor tract damage in patients with early RRMS: predominant impact of spinal cord lesions on motor function.
    Chouteau R; Combès B; Bannier E; Snoussi H; Ferré JC; Barillot C; Edan G; Sauleau P; Kerbrat A
    J Neurol; 2019 Sep; 266(9):2294-2303. PubMed ID: 31175433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis.
    Brownlee WJ; Altmann DR; Prados F; Miszkiel KA; Eshaghi A; Gandini Wheeler-Kingshott CAM; Barkhof F; Ciccarelli O
    Brain; 2019 Aug; 142(8):2276-2287. PubMed ID: 31342055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis.
    Bischof A; Papinutto N; Keshavan A; Rajesh A; Kirkish G; Zhang X; Mallott JM; Asteggiano C; Sacco S; Gundel TJ; Zhao C; Stern WA; Caverzasi E; Zhou Y; Gomez R; Ragan NR; Santaniello A; Zhu AH; Juwono J; Bevan CJ; Bove RM; Crabtree E; Gelfand JM; Goodin DS; Graves JS; Green AJ; Oksenberg JR; Waubant E; Wilson MR; Zamvil SS; ; Cree BAC; Hauser SL; Henry RG
    Ann Neurol; 2022 Feb; 91(2):268-281. PubMed ID: 34878197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study.
    Boster A; Hreha S; Berger JR; Bao F; Penmesta R; Tselis A; Endress C; Zak I; Perumal J; Caon C; Vazquez J; Tyler KL; Racke MK; Millis S; Khan O
    Arch Neurol; 2009 May; 66(5):593-9. PubMed ID: 19433659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis.
    Gavoille A; Rollot F; Casey R; Kerbrat A; Le Page E; Bigaut K; Mathey G; Michel L; Ciron J; Ruet A; Maillart E; Labauge P; Zephir H; Papeix C; Defer G; Lebrun-Frenay C; Moreau T; Berger E; Stankoff B; Clavelou P; Thouvenot E; Heinzlef O; Pelletier J; Al-Khedr A; Casez O; Bourre B; Cabre P; Wahab A; Magy L; Camdessanché JP; Doghri I; Moulin S; Ben-Nasr H; Labeyrie C; Hankiewicz K; Neau JP; Pottier C; Nifle C; Manchon E; Lapergue B; Wiertlewski S; De Sèze J; Vukusic S; Laplaud DA;
    JAMA Neurol; 2024 Aug; 81(8):814-823. PubMed ID: 38949816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preferential spinal cord volume loss in primary progressive multiple sclerosis.
    Tsagkas C; Magon S; Gaetano L; Pezold S; Naegelin Y; Amann M; Stippich C; Cattin P; Wuerfel J; Bieri O; Sprenger T; Kappos L; Parmar K
    Mult Scler; 2019 Jun; 25(7):947-957. PubMed ID: 29781383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited utility of adding 3T cervical spinal cord MRI to monitor disease activity in multiple sclerosis.
    Lim TRU; Kumaran SP; Suthiphosuwan S; Espiritu AI; Jones A; Lin AW; Oh J; Bharatha A
    Mult Scler; 2024 Apr; 30(4-5):505-515. PubMed ID: 38419027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spinal cord and brain atrophy patterns in neuromyelitis optica spectrum disorder and multiple sclerosis.
    Hua T; Fan H; Duan Y; Tian D; Chen Z; Xu X; Bai Y; Li Y; Zhang N; Sun J; Li H; Li Y; Li Y; Zeng C; Han X; Zhou F; Huang M; Xu S; Jin Y; Li H; Zhuo Z; Zhang X; Liu Y
    J Neurol; 2024 Jun; 271(6):3595-3609. PubMed ID: 38558149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis.
    Thorpe JW; Kidd D; Moseley IF; Kenndall BE; Thompson AJ; MacManus DG; McDonald WI; Miller DH
    Neurology; 1996 Feb; 46(2):373-8. PubMed ID: 8614497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fingolimod reduces the clinical expression of active demyelinating lesions in MS.
    Signoriello E; Landi D; Monteleone F; Saccà F; Nicoletti CG; Buttari F; Sica F; Marfia GA; Di Iorio G; Lus G; Centonze D
    Mult Scler Relat Disord; 2018 Feb; 20():215-219. PubMed ID: 29433094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Grey matter involvement by focal cervical spinal cord lesions is associated with progressive multiple sclerosis.
    Kearney H; Miszkiel KA; Yiannakas MC; Altmann DR; Ciccarelli O; Miller DH
    Mult Scler; 2016 Jun; 22(7):910-20. PubMed ID: 26432854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
    Arnold DL; Calabresi PA; Kieseier BC; Liu S; You X; Fiore D; Hung S
    BMC Neurol; 2017 Feb; 17(1):29. PubMed ID: 28183276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.